CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Research & Development
-€107.2m
CAGR 3-Years
1%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Research & Development
-€1.8B
CAGR 3-Years
-43%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Research & Development
-€285.7m
CAGR 3-Years
-51%
CAGR 5-Years
-25%
CAGR 10-Years
-19%
Immatics NV
NASDAQ:IMTX
Research & Development
-€116.1m
CAGR 3-Years
-21%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Research & Development
-€67.7m
CAGR 3-Years
-18%
CAGR 5-Years
-6%
CAGR 10-Years
1%
Formycon AG
XETRA:FYB
Research & Development
-€11.5m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Research & Development?
Research & Development
-107.2m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Research & Development amounts to -107.2m EUR.

What is CureVac NV's Research & Development growth rate?
Research & Development CAGR 5Y
-21%

Over the last year, the Research & Development growth was -99%. The average annual Research & Development growth rates for CureVac NV have been 1% over the past three years , -21% over the past five years .

Back to Top